Paid Clinical Trials in Kansas

Kansas has 933 paid clinical trials enrolling now across cities including Kansas City, Overland Park and Westwood. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

State

City

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

933 clinical trials

↓ Download CSV

Deep Functional Phenotyping of the ALA Lung Health Cohort

for Lung Diseases

12 locations incl. Birmingham

Sponsor: Johns Hopkins University

Sex: All·Age: 25 - 35·Accepts healthy volunteers

Code: NCT06177717·Recruiting

Apply to this trial

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

for Advanced Solid Tumors With KRAS G12C Mutations

Drug: FMC-376

15 locations incl. La Jolla

Sponsor: Frontier Medicines Corporation

Sex: All·Age: 18+

Code: NCT06244771·Phase 1, Phase 2·Recruiting

Apply to this trial

Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study

for Autonomic Dysfunction

8 locations incl. Overland Park

Sponsor: Kansas City Heart Rhythm Research Foundation

Sex: All·Age: 18 - 85

Code: NCT06289413·Recruiting

Apply to this trial

HIT-Stroke Trial 2

for Stroke

3 locations incl. Newark

Sponsor: University of Cincinnati

Sex: All·Age: 30 - 85

Code: NCT06268041·Recruiting

Apply to this trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

for Multiple Myeloma

Drug: Elranatamab

97 locations incl. Mobile

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06152575·Phase 3·Recruiting

Apply to this trial

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

for Duchenne Muscular Dystrophy

25 locations incl. Little Rock

Sponsor: Sarepta Therapeutics, Inc.

Sex: Male·Age: 4+

Code: NCT06270719·Enrolling By Invitation

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

490 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

To Develop a Walking Exercise Program for Non-ambulatory Stroke Survivors

for Stroke

1 location in Kansas City

Sponsor: University of Kansas Medical Center

Sex: All·Age: 18 - 80

Code: NCT06247553·Recruiting

Apply to this trial

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

for Idiopathic Pulmonary Fibrosis

19 locations incl. La Mesa

Sponsor: Cumberland Pharmaceuticals

Sex: All·Age: 40+

Code: NCT05571059·Phase 2·Recruiting

Apply to this trial

Mobile Health for Adherence in Breast Cancer Patients

for Anatomic Stage IV Breast Cancer AJCC v8

499 locations incl. Fairbanks

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06112613·Recruiting

Apply to this trial

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

for Nodular Lymphocyte Predominant B-Cell Lymphoma

Drug: Mosunetuzumab

35 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05886036·Phase 2·Recruiting

Apply to this trial

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

for Rheumatoid Arthritis

4 locations incl. San Francisco

Sponsor: University of Colorado, Denver

Sex: All·Age: 18 - 90

Code: NCT06397677·Recruiting

Apply to this trial

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

for Heart Failure

Drug: Finerenone

77 locations incl. Birmingham

Sponsor: Colorado Prevention Center

Sex: All·Age: 18+

Code: NCT06008197·Phase 3·Recruiting

Apply to this trial

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

for Metastatic Head-and-neck Squamous-cell Carcinoma

28 locations incl. Gilbert

Sponsor: AVEO Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06064877·Phase 3·Recruiting

Apply to this trial

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

for Hepatocellular Carcinoma

Drug: Livmoniplimab

13 locations incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06109272·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

for Acute Myeloid Leukemia

8 locations incl. Duarte

Sponsor: GluBio Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06146257·Phase 1·Recruiting

Apply to this trial

Obeticholic Acid for Prevention in Barrett's Esophagus

for Barrett Esophagus

8 locations incl. Kansas City

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT04939051·Phase 2·Recruiting

Apply to this trial

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

for Relapsed/Refractory Non-Hodgkin Lymphoma

14 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06090539·Phase 1, Phase 2·Recruiting

Apply to this trial

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

for Hypertension

70 locations incl. Scottsdale

Sponsor: Orchestra BioMed, Inc

Sex: All·Age: 18+

Code: NCT06059638·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

for Major Depressive Disorder

40 locations incl. Bellflower

Sponsor: Axsome Therapeutics, Inc.

Sex: All·Age: 18 - 65

Code: NCT06223880·Phase 4·Recruiting

Apply to this trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

for Prostate Cancer

27 locations incl. Birmingham

Sponsor: Clarity Pharmaceuticals Ltd

Sex: Male·Age: 18+

Code: NCT06056830·Phase 3·Recruiting

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting

Apply to this trial

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

for Idiopathic Inflammatory Myopathy

31 locations incl. Orange

Sponsor: Cabaletta Bio

Sex: All·Age: 6 - 75

Code: NCT06154252·Phase 2, Phase 3·Recruiting

Apply to this trial

Vitamin D for Prostate Endocrine Therapy

for Stage I Prostate Cancer AJCC v8

51 locations incl. Newark

Sponsor: University of Rochester

Sex: Male·Age: 50+

Code: NCT05838716·Phase 3·Recruiting

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

388 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting

Apply to this trial

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

for Locally Advanced Head and Neck Squamous Cell Carcinoma

70 locations incl. Birmingham

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06129864·Phase 3·Recruiting

Apply to this trial

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

for Breast Cancer

79 locations incl. Phoenix

Sponsor: BriaCell Therapeutics Corporation

Sex: All·Age: 18+

Code: NCT06072612·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

for Myeloproliferative Neoplasms

Drug: Ruxolitinib

13 locations incl. Duarte

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06034002·Phase 1·Recruiting

Apply to this trial

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

for Esophageal Stricture

34 locations incl. Birmingham

Sponsor: GIE Medical

Sex: All·Age: 22+

Code: NCT05561114·Phase 3·Recruiting

Apply to this trial

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

for NASH With Fibrosis

Drug: Efruxifermin

205 locations incl. Birmingham

Sponsor: Akero Therapeutics, Inc

Sex: All·Age: 18 - 80

Code: NCT06215716·Phase 3·Recruiting

Apply to this trial

NLit and Outcomes in HNC Survivor-Caregiver Dyads

for Head and Neck Cancer

1 location in Kansas City

Sponsor: University of Kansas Medical Center

Sex: All·Age: 18+

Code: NCT07021885·Recruiting

Apply to this trial

Hyperpolarized 129Xe MRI Lung Health Cohort

for Healthy

6 locations incl. Chicago

Sponsor: University of Kansas Medical Center

Sex: All·Age: 25 - 35

Code: NCT05766384·Recruiting

Apply to this trial

The Fourth Left Atrial Appendage Occlusion Study

for Atrial Fibrillation

51 locations incl. Birmingham

Sponsor: Hamilton Health Sciences Corporation

Sex: All·Age: 18+

Code: NCT05963698·Recruiting

Apply to this trial

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

for Heart Failure NYHA Class II

47 locations incl. Phoenix

Sponsor: Endotronix, Inc.

Sex: All·Age: 18+

Code: NCT05934487·Recruiting

Apply to this trial

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

for Lung Cancer Diagnosis

36 locations incl. Los Angeles

Sponsor: Freenome Holdings Inc.

Sex: All·Age: 50+

Code: NCT06122077·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

536 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

for Aortic Valve Insufficiency

32 locations incl. Newport Beach

Sponsor: Edwards Lifesciences

Sex: All·Age: All ages

Code: NCT05172973·Recruiting

Apply to this trial

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

for Hematologic Malignancy

17 locations incl. Duarte

Sponsor: CRISPR Therapeutics AG

Sex: All·Age: 18+

Code: NCT06208878·Enrolling By Invitation

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

for Stage IIC Prostate Cancer AJCC v8

Drug: Relugolix

1 location in Kansas City

Sponsor: University of Kansas Medical Center

Sex: Male·Age: 18+

Code: NCT06129851·Phase 2·Not Yet Recruiting

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

for Obesity

49 locations incl. Chandler

Sponsor: Eli Lilly and Company

Sex: All·Age: 18 - 75

Code: NCT06143956·Phase 2·Recruiting

Apply to this trial